EcoDrugPlus

Neurotrophic Tyrosine Kinase, Receptor, Type 2b

Ensembl ID : ENSORLG00000023491
Gene Symbol: NTRK2B
1 Cross references
200 Possible Orthologues:

Neurotrophic Tyrosine Kinase, Receptor, Type 2b

Ensembl ID : ENSORLG00000004637
Gene Symbol: NTRK2B
1 Cross references
174 Possible Orthologues:

Nfe2 Like Bzip Transcription Factor 2a

Ensembl ID : ENSORLG00000017568
Gene Symbol: NFE2L2A
4 Cross references
216 Possible Orthologues:

Nicastrin

Ensembl ID : ENSORLG00000002927
Gene Symbol: NCSTN
4 Cross references
203 Possible Orthologues:

Nicotinamide Phosphoribosyltransferase

Ensembl ID : ENSORLG00000013189
Gene Symbol: NAMPT
4 Cross references
225 Possible Orthologues:

Nischarin

Ensembl ID : ENSORLG00000019759
Gene Symbol: NISCH
4 Cross references
209 Possible Orthologues:

Notch Receptor 1

Ensembl ID : ENSORLG00000000636
Gene Symbol: NOTCH1
4 Cross references
201 Possible Orthologues:

Notch Receptor 3

Ensembl ID : ENSORLG00000005980
Gene Symbol: NOTCH3
4 Cross references
197 Possible Orthologues:

Nuclear Factor Kappa B Subunit 1

Ensembl ID : ENSORLG00000030524
Gene Symbol: NFKB1
4 Cross references
200 Possible Orthologues:

Nuclear Receptor Subfamily 1, Group H, Member 3

Ensembl ID : ENSORLG00000001286
Gene Symbol: NR1H3
4 Cross references
391 Possible Orthologues:

Nuclear Receptor Subfamily 1, Group H, Member 4

Ensembl ID : ENSORLG00000011270
Gene Symbol: NR1H4
4 Cross references
387 Possible Orthologues:

Nuclear Receptor Subfamily 3 Group C Member 1

Ensembl ID : ENSORLG00000001565
Gene Symbol: NR3C1
4 Cross references
205 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).